Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Haematopoietic stem cell transplant (HSCT) recipients have deficiencies in their adaptive immunity against vaccine preventable diseases. National and International guidance recommends that HSCT recipients are considered 'never vaccinated' and offered a comprehensive course of revaccination. This position statement aims to draw upon the current evidence base and existing guidelines, and align this with national vaccine availability and licensing considerations in order to recommend a pragmatic and standardised re-vaccination schedule for adult and paediatric HSCT recipients in the UK.

Original publication

DOI

10.1016/j.jinf.2022.11.005

Type

Journal article

Journal

J Infect

Publication Date

01/2023

Volume

86

Pages

1 - 8

Keywords

Haematopoietic stem cell transplant, Immunisation, Vaccination, Adult, Child, Humans, Bone Marrow, Hematopoietic Stem Cell Transplantation, Leukemia, Transplant Recipients, Vaccination, Vaccines